RESTYLANE SKINBOOSTER VITAL LIGHT LIDOCAINE

RESTYLANE SKINBOOSTER VITAL LIGHT LIDO is a gel:
- Sterile and transparent stabilised hyaluronic acid, not of animal origin.
- Composed of lidocaine hydrochloride at 0.3%.
- Indicated for improving elasticity, radiance and hydration of the skin.
- It guarantees safety, traceability and ease of use.

- GALDERMA
- NAME: RESTYLANE SKINBOOSTER VITAL LIGHT LIDO
- COMPOSITION: Stabilised hyaluronic acid 12 mg/mL, Lidocaine hydrochloride 3 mg/mL, Phosphate-buffered saline solution q.s.
- PRESENTATION: 1 x 1 ml.
- INDICATIONS: Integrates naturally into the skin, helping to improve its elasticity.
- NEEDLES: 2 x 29G x½”.
- INJECTION DEPTH: Derma.
- DURATION: Approximately 6 months.
- USE: Strict medical use.

- Syringes: 1 x 1 ml.
- Needles: 2 x 29G x½”.
- Each box contains one 1 mL syringe of RESTYLANE SKINBOOSTER VITAL LIGHT LIDO, 2 sterile single-use 29G x ½” needles reserved exclusively for injection of RESTYLANE SKINBOOSTER VITAL LIGHT LIDO, instructions for use and labels to ensure traceability.

Face, in particular: lower cheek/jawline and upper neck.

Stabilised hyaluronic acid 12 mg/mL, Lidocaine hydrochloride 3 mg/mL, Phosphate-buffered saline q.s.

- To minimise the risk of potential complications, this product should only be used by healthcare professionals with adequate training, experience and knowledge of the anatomy of the treated area and surrounding tissues.
- Healthcare professionals are encouraged to discuss all potential risks of soft tissue injections with patients prior to treatment, making sure they are aware of the signs and symptoms of possible complications.
- Injection procedures carry a risk of infection. Aseptic techniques and standard practices must be observed to prevent cross-infection.
- Use with caution in immunosuppressed patients.
- Special care must be taken when treating areas in the vicinity of permanent implants.
- Localised ischaemia/necrosis and scar formation may occur after injections near or within blood vessels. Caution is required in patients who have undergone previous surgery in the area to be treated.
- Special care should be taken to avoid injections that are too voluminous or too superficial in areas of the face with poor soft tissue support or coverage, to prevent the formation of palpable nodules.
- Injection procedures may cause reactivation of latent or subclinical herpetic infections.
- Bruising or bleeding at the injection sites may occur. The device should be used with caution in patients who have been treated with thrombolytics, anticoagulants or drugs that inhibit platelet aggregation, such as aspirin or non-steroidal anti-inflammatory drugs, in the preceding two weeks.
- Persons with skin phototype IV-VI may be predisposed to keloid formation. Ensure that the patient has no history of previous keloids.
- Patients with unrealistic expectations are not suitable candidates for treatment.
- Do not use the product if the packaging is damaged.

RESTYLANE SKINBOOSTER VITAL LIGHT LIDO is contraindicated in the following cases
- Patients with known hypersensitivity to hyaluronic acid fillers, lidocaine or amide-type local anaesthetics.
- Patients with a history of hypersensitivity to streptococcal proteins, as the product may contain traces of these proteins.
- Patients with coagulation disorders.
- Patients with porphyria.
- Patients with a documented history of keloids.

RESTYLANE SKINBOOSTER VITAL LIGHT LIDO is intended to improve skin elasticity in the lower cheek/jawline area and upper neck. The lidocaine in the gel increases overall comfort during treatment.

The contents of the syringe are sterilised by moist heat. Needles are sterilised by irradiation.